Ceva Santé Animale key facts
as of Oct 2026- Manufacturer of veterinary pharmaceutical products intended to be used for companion and production animals.
- Ceva Santé Animale is valued at approximately $9.7B as of Oct 2026 (last reported valuation).
- It has raised $12.6B; the latest was Buyout/LBO in May 2025.
- Notable investors include Temasek Holdings, Sagard, Societe Generale Capital Partenaires, EMZ Partners, Sofiproteol — 11 tracked in total.
- Status: Privately Held (backing).
Ceva Santé Animale's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Ceva Santé Animale: the Monday email on marks, rounds and moves
Ceva Santé Animale funding rounds
No funding rounds for Ceva Santé Animale are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ceva Santé Animale
11+Ceva Santé Animale valuation
Ceva Santé Animale's last reported valuation was $9.7 billion in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Ceva Santé Animale investors
11 investors are on record for Ceva Santé Animale, including Temasek Holdings, Sagard, Societe Generale Capital Partenaires and EMZ Partners.
About Ceva Santé Animale
Manufacturer of veterinary pharmaceutical products intended to be used for companion and production animals. The company offers products for cardiology, behavior and locomotion, and swine and ruminants, as well as for antibiotic therapy, poultry vaccines, vaccination equipment, pharmaceuticals and disinfectants, thereby helping concerned authorities to protect the health of humans and animals.
- Sector
- Materials and Resources
- HQ
- Libourne, France
- Founded
- 1999
- Employees
- 7,200
- Website
- ceva.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.